Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

New Agent Found to Suppress Cognitive Impairment of Alzheimer’s Disease

By BiotechDaily International staff writers
Posted on 25 Nov 2013
A unique new compound has been shown to prevent cognitive impairment and oxidative stress in animal lab models and may ultimately be useful in treating Alzheimer’s disease (AD).

This new findings on the compound, IRL-1620, were presented at the 2013 American Association of Pharmaceutical Scientists (AAPS) annual meeting and exposition, the world’s largest pharmaceutical sciences meeting, held in San Antonio (TX, USA), November 10-14, 2013.

Anil Gulati, MD, PhD, FCP, and Seema Briyal, PhD, along with their colleagues from Midwestern University (Downers Grove, IL, USA), administered Amyloid beta (Aβ), a key component of specific deposits located in AD patients’ brains, to normal and diabetic rats on days 1, 7, and 14. The lab rat’s spatial learning and memory were assessed in a Morris water maze. The pool was separated into four equal quadrants, and an escape platform was hidden below the surface at a fixed location in one of the quadrants.

The rats had to locate the platform within 60 seconds. The average time it took on day 4 for Aβ-treated rats to locate the platform was 55.05 seconds, though most of this group was not able to find it in the allotted time. Aβ rats treated with IRL-1620 were able to find the platform in 26.53 seconds, nearly 50% the time. After five days, Aβ rats treated with IRL-1620 showed a 60% improvement in learning and memory.

“Our research is based on the idea of using the endothelin [ET] system in the treatment of AD,” said Dr. Gulati. “The ET system is traditionally known to play a role in the regulation of blood flow. This is important in the potential treatment of AD since disturbances in blood flow could damage the brain’s ability to clear damaging particles, leading to a buildup of toxic substances and cognitive impairment.”

The next stage of the research is to additionally study the endothelin receptor type B’s mechanisms of neuroprotection and to look into possible resulting tissue changes following AD.

The US Food and Drug Administration (FDA) has approved five medications to treat the symptoms of AD. Current agents help disguise the symptoms but do not treat the underlying disease. A breakthrough AD treatment would target the underlying disease and stop or delay the cell damage that ultimately leads to the aggravation of symptoms.

Related Links:

Midwestern University



Channels

Genomics/Proteomics

view channel
Image: Transmission electron micrograph of norovirus particles in feces (Photo courtesy of Wikimedia Commons).

Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.